Edition:
India

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

46.88USD
2:29am IST
Change (% chg)

$-0.22 (-0.48%)
Prev Close
$47.10
Open
$46.65
Day's High
$47.40
Day's Low
$45.75
Volume
145,657
Avg. Vol
232,419
52-wk High
$60.15
52-wk Low
$19.30

Chart for

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $4,359.11
Shares Outstanding(Mil.): 78.97
Dividend: --
Yield (%): --

Financials

BRIEF-Fibrogen Inc reports Q3 loss per share $0.50

* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S

09 Nov 2017

BRIEF-Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease

* Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD)

18 Oct 2017

BRIEF-Fibrogen's ‍Pamrevlumab was well tolerated with no safety risks

* ‍Announced results from co's phase 2b randomized, double-blind, placebo-controlled study in patients with idiopathic pulmonary fibrosis​

13 Sep 2017

BRIEF-Fibrogen announces pricing of follow-on offering of common stock

* Fibrogen, Inc. announces pricing of follow-on offering of common stock

16 Aug 2017

BRIEF-FibroGen announces proposed follow-on offering of common stock

* Fibrogen Inc announces proposed follow-on offering of common stock

15 Aug 2017

BRIEF-Fibrogen ‍net loss per diluted share for quarter ended June 30 was $0.48

* Fibrogen Inc - ‍net loss per basic and diluted share for quarter ended June 30, 2017 was $0.48 - SEC filing​

08 Aug 2017

BRIEF-Fibrogen Inc reports Q2 loss per share $0.48

* Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S

08 Aug 2017

Earnings vs. Estimates